FindTrial
Sign In

The Application of Holographic Imaging Technology in the Diagnosis and Treatment of Prostate Cancer

The Application of Holographic Imaging Technology in the Diagnosis and Treatment of Prostate Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104865
Enrollment
Unknown
Registered
2025-06-25
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Control group:MRI-TURS-guided prostate needle biopsy, such as robot-assisted radical prostatectomy in patients with conventional pathology suggestive of prostate cancer
Experimental group:Hologram-guided prostate biopsy is performed, and if the puncture result is positive, radical prostatectomy with hologram and robotic visual field fusion is performed

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. Prostate-specific antigen (PSA) >10ng/ml; 2. Prostate Imaging Reporting and Data System (PI-RADS) score>=4 points; 3. Imaging examination showed localized prostate cancer.

Exclusion criteria

Exclusion criteria: 1. Previous diagnosis of prostate adenocarcinoma; 2. Imaging examination showed distant metastasis of prostate cancer or lymph node metastasis; 3. Previous history of benign prostatic hyperplasia surgery.

Design outcomes

Primary

MeasureTime frame
Positive rate;Time of operation;Peroperative bleeding;Hospital stays;Number of admissions;Psychological burden score;—

Countries

China

Contacts

Public ContactXuefei Ding

Northern Jiangsu People's Hospital

xuefeid@126.com+86 180 5106 1234

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026